S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
$0.08
$0.13
$0.07
$1.95
$3.03M1.973.47 million shs3.46 million shs
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
$9.06
-1.3%
$8.70
$2.80
$8.97
$326.69M0.6337,931 shs456,563 shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
+3.45%-6.25%-39.17%-44.95%+8,399,900.00%
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
0.00%-2.27%+7.09%+49.01%+37.27%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/AN/AN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
$14.73M0.21N/AN/A$0.12 per share0.70
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/A$7.41 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
-$9.64M-$3.82N/A1.20N/A-65.46%-150.14%-53.48%N/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
-$89.48M-$2.42N/AN/AN/A-29.62%-28.20%N/A

Latest NBY, SBTX, HVO, and RLM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/26/2024Q4 2023
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/A-$0.95-$0.95-$0.57N/A$3.73 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/AN/AN/AN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/A
1.67
1.00
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/A
67.87
67.87

Ownership

Institutional Ownership

CompanyInstitutional Ownership
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
23.25%
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
74.89%

Insider Ownership

CompanyInsider Ownership
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
1.30%
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
34.40%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
2436.06 million35.59 millionNot Optionable
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
8336.06 million23.65 millionNot Optionable

NBY, SBTX, HVO, and RLM Headlines

SourceHeadline
Silverback Therapeutics (NASDAQ:SBTX) Trading Down 2%Silverback Therapeutics (NASDAQ:SBTX) Trading Down 2%
marketbeat.com - April 3 at 2:15 AM
ARS Pharmaceuticals Inc (SPRY)ARS Pharmaceuticals Inc (SPRY)
uk.investing.com - May 11 at 1:32 PM
Wild IslesWild Isles
wwf.org.uk - March 12 at 9:31 AM
A look back at RNA Therapeutics – day oneA look back at RNA Therapeutics – day one
pharmaphorum.com - February 24 at 12:35 AM
SPRY ARS Pharmaceuticals, Inc.SPRY ARS Pharmaceuticals, Inc.
seekingalpha.com - January 24 at 8:04 PM
ARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake After MergerARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake After Merger
247wallst.com - November 22 at 6:29 AM
Dr. Sarina Tanimoto Discloses Position in SBTX / Silverback TherapeuticsDr. Sarina Tanimoto Discloses Position in SBTX / Silverback Therapeutics
nasdaq.com - November 18 at 8:19 PM
ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including AnaphylaxisARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis
finance.yahoo.com - November 10 at 6:41 PM
ARS Pharmaceuticals Closes Merger with Silverback TherapeuticsARS Pharmaceuticals Closes Merger with Silverback Therapeutics
finance.yahoo.com - November 8 at 5:59 PM
Silverback : FDA Accepts ARS Pharms NDA For Neffy For Treatment Of Allergic ReactionsSilverback : FDA Accepts ARS Pharm's NDA For Neffy For Treatment Of Allergic Reactions
markets.businessinsider.com - October 28 at 8:15 AM
FDA accepts ARS Pharma’s NDA for NeffyFDA accepts ARS Pharma’s NDA for Neffy
thepharmaletter.com - October 24 at 10:29 AM
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HIL, SBTX, COWN, AERISHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HIL, SBTX, COWN, AERI
kentuckytoday.com - October 23 at 7:22 PM
Silverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including AnaphylaxisSilverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis
finance.yahoo.com - October 21 at 7:59 AM
Is Silverback Therapeutics Inc (SBTX) Stock a Good Investment?Is Silverback Therapeutics Inc (SBTX) Stock a Good Investment?
aaii.com - October 19 at 11:52 AM
SHAREHOLDER ALERT: The M&A Class Action Firm is Investigating the Merger – RFP, SBTX, AAWW, COWNSHAREHOLDER ALERT: The M&A Class Action Firm is Investigating the Merger – RFP, SBTX, AAWW, COWN
bakersfield.com - October 12 at 11:07 PM
INVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBTINVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBT
markets.businessinsider.com - September 17 at 5:10 AM
SBTX Silverback Therapeutics, Inc.SBTX Silverback Therapeutics, Inc.
seekingalpha.com - September 15 at 10:58 PM
SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FTAI, SBTX, CVET, GBTSHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FTAI, SBTX, CVET, GBT
markets.businessinsider.com - September 6 at 11:53 AM
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZYSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZY
markets.businessinsider.com - August 23 at 6:32 PM
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates VIVO, HNGR, SBTXSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates VIVO, HNGR, SBTX
apnews.com - August 17 at 12:02 PM
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates IEA, BBQ, SBTXSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates IEA, BBQ, SBTX
apnews.com - August 11 at 1:33 AM
SHAREHOLDER ALERT: Weiss Law Reminds SBTX, LJPC, CNVY, and DRE Shareholders About Its Ongoing InvestigationsSHAREHOLDER ALERT: Weiss Law Reminds SBTX, LJPC, CNVY, and DRE Shareholders About Its Ongoing Investigations
morningstar.com - July 30 at 7:00 AM
INVESTIGATION ALERT: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZYINVESTIGATION ALERT: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZY
apnews.com - July 28 at 2:21 AM
Shareholder Alert - The M&A Class Action Firm Announces the Investigation of Silverback Therapeutics, Inc. - SBTXShareholder Alert - The M&A Class Action Firm Announces the Investigation of Silverback Therapeutics, Inc. - SBTX
benzinga.com - July 27 at 9:21 PM

New MarketBeat Followers Over Time

Company Descriptions

NovaBay Pharmaceuticals logo

NovaBay Pharmaceuticals

NYSE:NBY
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
Silverback Therapeutics logo

Silverback Therapeutics

NASDAQ:SBTX
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.